Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.

Rheumatology (Oxford) · 2020 · PMC7516108 · PMID 32107560

Europe PMC DOI

hedged sentences

0.0950

closest p · 1.9× alpha

0.0950

boldest claim

The sentences

did not reach statistical significanceP = 0.095so close (0.05 < p ≤ 0.1)

Increased remission attainment with atacicept 150 mg vs placebo at week 24 was also observed, but this did not reach statistical significance [13.7 vs 3.8%, OR 3.98 (95% CI: 0.78, 20.15), P = 0.095] ( Fig. 1B ).

also in 111,027 other papers

showed a trendno p-value reported

These results are consistent with the increases in SRI-4 and SRI-6 response rates observed with atacicept 150 mg vs placebo in the mITT population [ 28 ], which also showed a trend for treatment effect that did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.